Skip to main content

Obsidian Therapeutics, Inc.

corporate_fare Company Profile

Obsidian Therapeutics, Inc.

OBX·NASDAQ·Life Sciences·CIK 0002130606

Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on pioneering engineered cell and gene therapies, particularly for solid tumors. The company leverages its proprietary cytoDRiVE® platform, which utilizes drug-responsive domains (DRDs) to precisely control protein activity in cells using FDA-approved small-molecule drugs. This technology aims to enhance the efficacy and safety of treatments by enabling tunable protein expression. Obsidian Therapeutics is developing tumor-infiltrating lymphocyte (TIL) cell therapies, with its lead candidate, OBX-115, currently in clinical trials for advanced melanoma and non-small cell lung cancer (NSCLC). The company announced a definitive merger agreement with Galera Therapeutics in April 2026, becoming a publicly traded company on Nasdaq under the ticker 'OBX'. This merger was supported by a $350 million private placement to fund clinical operations through 2028. Obsidian Therapeutics has offices in Cambridge and Bedford, Massachusetts, USA. Sources: [1] https://intuitionlabs.ai/companies/biotech/obsidian-therapeutics [2] https://www.foresitecapital.com/portfolio/obsidian-therapeutics-inc/ [3] https://obsidiantx.com/ [4] https://www.businesswire.com/news/home/20260803549139/en/Obsidian-Therapeutics-Completes-Closing-of-Transaction-with-Galera-Therapeutics-and-Previously-Announced-Private-Placement-of-%24350-Million [5] https://startupintros.com/orgs/obsidian-therapeutics [6] https://tracxn.com/d/companies/obsidiantherapeutics/__gv0si6OxT5M8G_ipEBLhju3knJSGytY5xGdJY4cdLKA

Obsidian Therapeutics, Inc. (NASDAQ:OBX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for OBX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 5 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for OBX spans 10-Q, 8-K, 8-K/A.

Recent high-impact activity:

  • Obsidian 10-Q: $50.7M Q3 Loss, $324.4M Cash Into 2H 2028, New Director
  • Obsidian Posts Q3 Loss of $50.7M With $324.4M Cash and 67% ORR in Melanoma
  • Obsidian's amsoki-cel Hits 67% Response Rate in Advanced Melanoma
  • Obsidian Files Merger Financials: $350M PIPE Alleviates Going Concern
  • Obsidian Therapeutics finalizes reverse merger with Galera, secures $350M PIPE, and debuts on Nasdaq as OBX

Financial Snapshot

Fiscal year ended September 30, 2025
Revenue
$9.91M
Net Income
-$46.13M
Diluted EPS
-$1.01
Op. Cash Flow
-$10.11M
Free Cash Flow
-$10.14M
Gross Profit
$5.01M
Operating Income
-$37.69M
Cash & Equivalents
$3.27M
Total Debt
$6.18M
Debt / Equity
-18.41×
Net Margin
-465.4%
Shares Outstanding
45.47M sh
Source: 10-K · filed 2026-01-28 · accession 0001493152-26-004073

Short Interest & Short Volume

3.94 days to cover

FINRA reported short interest of 1,184,895 shares in OBX as of the October 30, 2026 settlement, a 9.6% increase from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 44.0% of OBX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,184,895 shares as of October 30, 2026
Change vs prior period▲ 9.6%
Days to cover3.94 at avg daily volume of 300,553
Daily short volume (FINRA facilities)44.0% of 175,480 shares on November 20, 2026
5-day average short volume67.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for OBX, detected from its recent SEC filings.

1 shelf registration

29.2M PIPE Shares Registered for Resale · Selling Stockholders Identified

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with O →
$12
52-week range · as of 2026-11-12 $9.6 – $49.97
Market cap
$741.29M
Volume
336.5K (0.7× avg)
3-mo avg 497.2K
Live data · 2026-11-21 20:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed OBX - Latest Insights

OBX
Nov 12, 2026, 4:13 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.48
Real-time Price: $12.00 info
Change: -$0.480 (-4%) info
Market Cap: $741.289M info
OBX
Nov 12, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.48
Real-time Price: $12.00 info
Change: -$0.480 (-4%) info
Market Cap: $741.289M info
OBX
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $12.48
Real-time Price: $12.00 info
Change: -$0.480 (-4%) info
Market Cap: $741.289M info
OBX
Aug 14, 2026, 4:29 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $19.00
Real-time Price: $12.00 info
Change: -$7.00 (-37%) info
Market Cap: $741.289M info
OBX
Aug 03, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $26.00
Real-time Price: $12.00 info
Change: -$14.00 (-54%) info
Market Cap: $741.289M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets